Trial Profile
Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 27 Aug 2018 Status changed from not yet recruiting to recruiting.
- 14 Aug 2018 New trial record